Published in Arthritis Rheum on May 01, 1998
Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis (2002) 1.85
Different glucocorticoids vary in their genomic and non-genomic mechanism of action in A549 cells. Br J Pharmacol (2002) 1.20
Glucocorticoids cause rapid dissociation of a T-cell-receptor-associated protein complex containing LCK and FYN. EMBO Rep (2006) 1.12
21-NO-prednisolone is a novel nitric oxide-releasing derivative of prednisolone with enhanced anti-inflammatory properties. Br J Pharmacol (2000) 1.04
Potent antiarthritic properties of a glucocorticoid derivative, NCX-1015, in an experimental model of arthritis. Proc Natl Acad Sci U S A (2002) 0.97
Glucocorticoids induce a near-total suppression of hyaluronan synthase mRNA in dermal fibroblasts and in osteoblasts: a molecular mechanism contributing to organ atrophy. Biochem J (2000) 0.95
Science review: mechanisms of impaired adrenal function in sepsis and molecular actions of glucocorticoids. Crit Care (2004) 0.91
The value of glucocorticoid co-therapy in different rheumatic diseases--positive and adverse effects. Arthritis Res Ther (2014) 0.87
Dexamethasone-induced autophagy mediates muscle atrophy through mitochondrial clearance. Cell Cycle (2014) 0.87
Post-infectious new daily persistent headache may respond to intravenous methylprednisolone. J Headache Pain (2010) 0.86
Nongenomic actions of adrenal steroids in the central nervous system. J Neuroendocrinol (2010) 0.84
Bioenergetics of immune cells to assess rheumatic disease activity and efficacy of glucocorticoid treatment. Ann Rheum Dis (2003) 0.84
Separating therapeutic efficacy from glucocorticoid side-effects in rodent arthritis using novel, liposomal delivery of dexamethasone phosphate: long-term suppression of arthritis facilitates interval treatment. Arthritis Res Ther (2009) 0.83
Effects of repeated intrathecal triamcinolone-acetonide application on cerebrospinal fluid biomarkers of axonal damage and glial activity in multiple sclerosis patients. Mol Diagn Ther (2014) 0.82
The inhibitory effect of dexamethasone on lymphocyte adhesion molecule expression and intercellular aggregation is not mediated by lipocortin 1. Clin Exp Immunol (1999) 0.80
A membrane glucocorticoid receptor mediates the rapid/non-genomic actions of glucocorticoids in mammalian skeletal muscle fibres. J Physiol (2013) 0.79
Mesenchymal stromal cells versus betamethasone can dampen disease activity in the collagen arthritis mouse model. Clin Exp Med (2013) 0.78
Nano-Drugs Based on Nano Sterically Stabilized Liposomes for the Treatment of Inflammatory Neurodegenerative Diseases. PLoS One (2015) 0.77
A single intravenous dose of prednisolone induces phosphatidylserine externalization, loss of surface marker expression and a 24-h net increase in human peripheral blood lymphocytes ex vivo. Rheumatol Int (2007) 0.77
Glucocorticosteroid dependent decrease in the activity of calcineurin in the peripheral blood mononuclear cells of patients with systemic lupus erythematosus. Ann Rheum Dis (2001) 0.76
Short-term effects of glucocorticoid therapy on biochemical markers of bone metabolism in Japanese patients: a prospective study. J Bone Miner Metab (2008) 0.76
[Glucocorticoid therapy in collagen diseases diseases]. Z Rheumatol (2005) 0.76
Further thoughts on the immunomodulatory role of glucocorticoids: comment on the article by Buttgereit et al. Arthritis Rheum (1999) 0.75
Comparison of High-Dose Corticosteroid Pulse Therapy and Combination Therapy Using Oral Cyclosporine with Low-Dose Corticosteroid in Severe Alopecia Areata. Ann Dermatol (2015) 0.75
Conjunctival Acute Graft-versus-Host Disease in Adult Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation: A Cohort Study. PLoS One (2016) 0.75
Recent advances in the understanding of renal inflammation and fibrosis in lupus nephritis. F1000Res (2017) 0.75
[Pulmonary emergencies in connective tissues disorders and vasculitides]. Z Rheumatol (2012) 0.75
[Steroids for optic nerve diseases?]. Ophthalmologe (2007) 0.75
[Cortisone therapy today]. Wien Klin Wochenschr (2003) 0.75
Effects of pulse methylprednisolone on inflammatory mediators in peripheral blood, synovial fluid, and synovial membrane in rheumatoid arthritis. Arthritis Rheum (1997) 2.12
Neutrophil trafficking into inflamed joints in patients with rheumatoid arthritis, and the effects of methylprednisolone. Arthritis Rheum (1996) 1.77
Guidelines for musculoskeletal ultrasound in rheumatology. Ann Rheum Dis (2001) 4.18
Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis (2008) 3.45
Arthritis of the finger joints: a comprehensive approach comparing conventional radiography, scintigraphy, ultrasound, and contrast-enhanced magnetic resonance imaging. Arthritis Rheum (1999) 3.42
Macrophages in rheumatoid arthritis. Arthritis Res (2000) 3.40
Human mononuclear phagocyte differentiation antigens. I. Patterns of antigenic expression on the surface of human monocytes and macrophages defined by monoclonal antibodies. J Immunol (1983) 3.26
Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol (2000) 3.05
Multiple actions of steroid hormones--a focus on rapid, nongenomic effects. Pharmacol Rev (2000) 2.94
Evaluation of a novel 7-joint ultrasound score in daily rheumatologic practice: a pilot project. Arthritis Rheum (2009) 2.57
Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis (2006) 2.51
EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees. Ann Rheum Dis (2004) 2.48
Ia+ T cells in synovial fluid and tissues of patients with rheumatoid arthritis. Arthritis Rheum (1981) 2.30
Identification of three major synovial lining cell populations by monoclonal antibodies directed to Ia antigens and antigens associated with monocytes/macrophages and fibroblasts. Scand J Immunol (1983) 2.10
Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis (2006) 2.07
Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Rheumatology (Oxford) (2007) 2.01
Attenuation of heart-rate variability in postmenopausal women on progestin-containing hormone replacement therapy. Lancet (1999) 1.98
Activated T cells in vivo and in vitro: divergence in expression of Tac and Ia antigens in the nonblastoid small T cells of inflammation and normal T cells activated in vitro. J Immunol (1984) 1.87
Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis (2008) 1.84
Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. Ann Rheum Dis (2005) 1.77
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis (2007) 1.70
Purification and partial sequencing of high-affinity progesterone-binding site(s) from porcine liver membranes. Eur J Biochem (1996) 1.70
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. Ann Rheum Dis (2012) 1.67
Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. Ann Rheum Dis (2003) 1.64
Prospective two year follow up study comparing novel and conventional imaging procedures in patients with arthritic finger joints. Ann Rheum Dis (2002) 1.63
Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis. Int Angiol (2012) 1.60
Subcutaneous crystal-storing histiocytosis associated with lymphoplasmacytic lymphoma (immunocytoma) Pathol Res Pract (1996) 1.57
Dominant negative myostatin produces hypertrophy without hyperplasia in muscle. FEBS Lett (2000) 1.50
Cloning and tissue expression of two putative steroid membrane receptors. Biol Chem (1998) 1.48
Bioenergetics of immune functions: fundamental and therapeutic aspects. Immunol Today (2000) 1.48
Association of citrullinated proteins with synovial exosomes. Arthritis Rheum (2006) 1.48
Screening for latent tuberculosis infection: performance of tuberculin skin test and interferon-γ release assays under real-life conditions. Ann Rheum Dis (2012) 1.46
Mechanical loading regulates NOS expression and activity in developing and adult skeletal muscle. Am J Physiol (1998) 1.46
Treatment of rheumatoid arthritis with an anti-CD4 monoclonal antibody. Arthritis Rheum (1991) 1.45
Cellular immune reactivity to recombinant OspA and flagellin from Borrelia burgdorferi in patients with Lyme borreliosis. Complexity of humoral and cellular immune responses. J Clin Invest (1992) 1.45
Full-length cDNA sequence of a progesterone membrane-binding protein from porcine vascular smooth muscle cells. Biochem Biophys Res Commun (1996) 1.40
No B cells--no active RA? Advances in B cell depletion in RA--repeated therapy under conditions of clinical practice. Rheumatology (Oxford) (2007) 1.39
[The therapy of systemic lupus erythematosus]. Dtsch Med Wochenschr (1996) 1.38
Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controls. Ann Rheum Dis (2007) 1.36
Hypoxia inducible factor (HIF) in rheumatology: low O2! See what HIF can do! Ann Rheum Dis (2005) 1.35
Coiling phagocytosis is the preferential phagocytic mechanism for Borrelia burgdorferi. Infect Immun (1992) 1.35
Nucleosomes are major T and B cell autoantigens in systemic lupus erythematosus. Arthritis Rheum (2000) 1.35
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Ann Rheum Dis (2010) 1.34
Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002). Ann Rheum Dis (2002) 1.33
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis (2008) 1.31
Persistence of Borrelia burgdorferi in ligamentous tissue from a patient with chronic Lyme borreliosis. Arthritis Rheum (1993) 1.27
[Prevention of adverse drug reactions in older patients]. Z Gerontol Geriatr (2007) 1.27
Preactivated peripheral blood monocytes in patients with essential hypertension. Hypertension (1999) 1.26
CD11c as a transcriptional biomarker to predict response to anti-TNF monotherapy with adalimumab in patients with rheumatoid arthritis. Clin Pharmacol Ther (2009) 1.25
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006. Ann Rheum Dis (2006) 1.25
Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003). Ann Rheum Dis (2003) 1.25
Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004. Ann Rheum Dis (2004) 1.24
T cell proliferation induced by Borrelia burgdorferi in patients with Lyme borreliosis. Autologous serum required for optimum stimulation. Arthritis Rheum (1991) 1.23
Segmental bone repair by tissue-engineered periosteal cell transplants with bioresorbable fleece and fibrin scaffolds in rabbits. Biomaterials (2000) 1.21
The European ankylosing spondylitis infliximab cohort (EASIC): a European multicentre study of long term outcomes in patients with ankylosing spondylitis treated with infliximab. Clin Exp Rheumatol (2011) 1.19
Immunological and functional characteristics of peripheral blood and synovial fluid lymphocytes from patients with rheumatoid arthritis. Scand J Immunol (1978) 1.19
Differential expression of Ia antigens by rheumatoid synovial lining cells. J Clin Invest (1987) 1.18
Detection of Borrelia burgdorferi by polymerase chain reaction in synovial membrane, but not in synovial fluid from patients with persisting Lyme arthritis after antibiotic therapy. Ann Rheum Dis (1998) 1.17
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010. Ann Rheum Dis (2011) 1.17
An optimized PCR leads to rapid and highly sensitive detection of Borrelia burgdorferi in patients with Lyme borreliosis. J Clin Microbiol (1997) 1.15
The stress protein BiP is overexpressed and is a major B and T cell target in rheumatoid arthritis. Arthritis Rheum (2001) 1.15
The binding of drugs to different polar lipids in vitro. Biochem Pharmacol (1979) 1.14
Prospective 7 year follow up imaging study comparing radiography, ultrasonography, and magnetic resonance imaging in rheumatoid arthritis finger joints. Ann Rheum Dis (2005) 1.13
Resorbable polyesters in cartilage engineering: affinity and biocompatibility of polymer fiber structures to chondrocytes. J Biomed Mater Res (1996) 1.13
A novel epitope on the C-terminus of SmD1 is recognized by the majority of sera from patients with systemic lupus erythematosus. J Clin Invest (1998) 1.12
Increased serum soluble CD14, ICAM-1 and E-selectin correlate with disease activity and prognosis in systemic lupus erythematosus. Lupus (2000) 1.11
Monocytes from systemic lupus erythematous patients are severely altered in phenotype and lineage flexibility. Ann Rheum Dis (2000) 1.11
Identification of known and novel genes in activated monocytes from patients with rheumatoid arthritis. Arthritis Rheum (2000) 1.10
Modulation of monocyte activation in patients with rheumatoid arthritis by leukapheresis therapy. J Clin Invest (1993) 1.09
Cellular immune response toward human articular chondrocytes. T cell reactivities against chondrocyte and fibroblast membranes in destructive joint diseases. Arthritis Rheum (1990) 1.09
Rapid, nongenomic steroid actions: A new age? Front Neuroendocrinol (2000) 1.09
Engineering of cartilage tissue using bioresorbable polymer carriers in perfusion culture. Biomaterials (1994) 1.08
Classic and non-classic progesterone receptors are both expressed in human spermatozoa. Horm Metab Res (2005) 1.08
Improvement in patient-reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Arthritis Rheum (2008) 1.08
Preferential cellular and humoral immune reactivities to native and denatured collagen types IX and XI in a patient with fatal relapsing polychondritis. J Rheumatol (1993) 1.08
Consensus statement on the initiation and continuation of tumour necrosis factor blocking therapies in rheumatoid arthritis. Ann Rheum Dis (2000) 1.08
Reduction of monocyte-macrophage activation markers upon anti-CD4 treatment. Decreased levels of IL-1, IL-6, neopterin and soluble CD14 in patients with rheumatoid arthritis. Clin Exp Immunol (1993) 1.08
Demonstration of Ia antigens on certain dendritic cells and on a novel elongate cell found in human synovial tissue. Scand J Immunol (1981) 1.07
Specific progesterone binding to a membrane protein and related nongenomic effects on Ca2+-fluxes in sperm. Endocrinology (1999) 1.07
Changes in cell surface antigen expression on human articular chondrocytes induced by gamma-interferon. Induction of Ia antigens. Arthritis Rheum (1987) 1.06
Biochemical characterization and microsequencing of a 205-kDa synovial protein stimulatory for T cells and reactive with rheumatoid factor containing sera. J Immunol (1996) 1.05
Autologous and allogeneic MLC-reactivity in patients with rheumatoid arthritis. J Clin Lab Immunol (1981) 1.05
Rapid typing of Borrelia burgdorferi sensu lato species in specimens from patients with different manifestations of Lyme borreliosis. J Clin Microbiol (2001) 1.04
Potential infectious agents in the induction of arthritides. Curr Opin Rheumatol (1996) 1.04
Equivalent doses and relative drug potencies for non-genomic glucocorticoid effects: a novel glucocorticoid hierarchy. Biochem Pharmacol (1999) 1.04
Gastrointestinal toxic side effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2-specific inhibitors. Am J Med (2001) 1.00
Autologous stem-cell transplantation in refractory autoimmune diseases after in vivo immunoablation and ex vivo depletion of mononuclear cells. Arthritis Res (2000) 1.00
First clinical evaluation of sagittal laser optical tomography for detection of synovitis in arthritic finger joints. Ann Rheum Dis (2004) 0.99
Bioenergetics of human peripheral blood mononuclear cell metabolism in quiescent, activated, and glucocorticoid-treated states. Biosci Rep (2000) 0.99
Proteasome alpha-type subunit C9 is a primary target of autoantibodies in sera of patients with myositis and systemic lupus erythematosus. J Exp Med (1996) 0.98
Mannheim classification of nongenomically initiated (rapid) steroid action(s). J Clin Endocrinol Metab (2000) 0.98
Application of monoclonal antibodies to the characterization of cells eluted from human articular cartilage. Expression of Ia antigens in certain diseases and identification of an 85-kD cell surface molecule accumulated in the pericellular matrix. Arthritis Rheum (1983) 0.98
Cytokines derived from alveolar macrophages induce fever after bronchoscopy and bronchoalveolar lavage. Am J Respir Crit Care Med (1997) 0.98
Evaluation of a new erosion score by musculoskeletal ultrasound in patients with rheumatoid arthritis: is US ready for a new erosion score? Clin Rheumatol (2014) 0.98
Chemical modification and structural analysis of the progesterone membrane binding protein from porcine liver membranes. Mol Cell Biochem (2001) 0.98
Reliability of the novel 7-joint ultrasound score: results from an inter- and intraobserver study performed by rheumatologists. Arthritis Care Res (Hoboken) (2012) 0.97
Coiling phagocytosis: when the zipper jams, the cup is deformed. Trends Microbiol (1998) 0.97